🇺🇸 FDA
Patent

US 9125833

Multimodal abuse resistant and extended release opioid formulations

granted A61KA61K31/44A61K9/485

Quick answer

US patent 9125833 (Multimodal abuse resistant and extended release opioid formulations) held by Relmada Therapeutics, Inc. expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Relmada Therapeutics, Inc.
Grant date
Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/44, A61K9/485, A61K9/4858, A61K9/4866